Objective: Quantification of the association between the intake of selenium and risk of pancreatic cancer is still conflicting. Thus, we conducted a meta-analysis to summarize the evidence from epidemiological studies of selenium intake with the risk of pancreatic cancer. Methods: Pertinent studies were identified by a search of PubMed and Web of Knowledge to July 2016. The random effect model was used. Sensitivity analysis and publication bias were conducted. Results: Data from 6 studies including 1,424 pancreatic cancer cases were used in this meta-analysis. Pooled results suggested that highest selenium intake amount versus lowest amount was significantly associated with the risk of pancreatic cancer [summary relative risk (RR) =0.659, 95% confidence interval (CI) =0.489-0.889, I2 = 47.6%]. The associations were significant both in case-control studies [RR =0.618, 95%CI =0.399-0.956, I2 = 59.1%] and Americas [RR =0.570, 95%CI =0.357-0.909, I2 = 65.6%]. No publication bias was found. Conclusions: Our analysis suggested that the higher intake of selenium might reduce the risk of pancreatic cancer.
- Pancreatic cancer
- ©2016 The Author(s)
This is an Accepted Manuscript; not the final Version of Record. You are encouraged to use the final Version of Record that, when published, will replace this manuscript and be freely available under a Creative Commons licence.